11:06 AM EDT, 08/29/2024 (MT Newswires) -- Kane Biotech ( KNBIF ) on Thursday said it published a new review article on DispersinB in the international, peer-reviewed, open-access journal, Pathogens.

The article is authored by Dr. Jeffrey Kaplan, the discoverer of the DispersinB enzyme and a consultant to Kane Biotech ( KNBIF ).

"DispersinB exhibits antibiofilm activity against more than 25 species of bacteria, suggesting that the enzyme may have applicability as a broad-spectrum antibiofilm agent. Considering Kane Biotech's ( KNBIF ) extensive biocompatibility testing and formulation studies involving DispersinB, I am optimistic about the commercial potential of products the company has in development that contain this enzyme," said Dr. Kaplan.

Kane Biotech was last seen up $0.01, to $0.15, on the TSX Venture Exchange.

Price: 0.16, Change: +0.01, Percent Change: +6.90